title: The mechanism of platelet aggregation induced by HLA-related antibodies.
abstract: Immune-mediated platelet activation is emerging as an important pathogenic mechanism of thrombosis. In vitro studies have suggested two distinct pathways for immune-mediated platelet activation; one involving clustering of platelet Fc gamma RIIa, the other involving platelet-associated complement activation. HLA-related antibodies have been shown to cause platelet aggregation, but the mechanism has not been clarified. We evaluated the mechanism of platelet aggregation induced by HLA-related antibodies from nine patients. Antibody to platelet Fc gamma RIIa failed to block platelet aggregation with 8/9 samples, indicating that engagement of platelet Fc gamma RIIa is not necessary for the platelet aggregation induced by HLA-related antibodies. In contrast, platelet aggregation was blocked by antibodies to human C8 (5/7) or C9 (7/7). F(ab')2 fragments of patient IgG failed to induce platelet activation although they bound to HLA antigen on platelets. Intact patient IgG failed to aggregate washed platelets unless aged serum was added. The activating IgG could be adsorbed by incubation with lymphocytes and eluted from the lymphocytes. These results indicate that complement activation is involved in the aggregation response to HLA-related antibodies. This is the first demonstration of complement-mediated platelet aggregation by clinical samples. Five of the patients developed thrombocytopenia in relationship to blood transfusion and two patients developed acute thromboembolic disease, suggesting that these antibodies and the complement-dependent pathway of platelet aggregation may be of clinical significance.
authors.affiliation: Department of Pathology, Ohio State University, Columbus, USA.
authors.forename: J T
authors.initials: JT
authors.lastname: Brandt
authors.forename: C J
authors.initials: CJ
authors.lastname: Julius
authors.forename: J M
authors.initials: JM
authors.lastname: Osborne
authors.forename: C L
authors.initials: CL
authors.lastname: Anderson
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D003167:Complement Activation; D003185:Complement C8 / Q000276:immunology; D003186:Complement C9 / Q000276:immunology; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007518:Isoantibodies / Q000276:immunology*; D008297:Male; D051379:Mice; D008875:Middle Aged; D010974:Platelet Aggregation / Q000276:immunology*; D017713:Platelet Transfusion / Q000009:adverse effects; D017452:Receptors, IgG / Q000276:immunology; D013921:Thrombocytopenia / Q000209:etiology; D013923:Thromboembolism / Q000209:etiology*; D065227:Transfusion Reaction
chemical_list: D000911:Antibodies, Monoclonal; D003185:Complement C8; D003186:Complement C9; D006680:HLA Antigens; D007074:Immunoglobulin G; D007518:Isoantibodies; D017452:Receptors, IgG